Cargando…

Potential value of heparin in COVID-19 related cardiovascular disease

There is increasing evidence that COVID-19 is a multi-organ infectious disease with respiratory system as its main clinical manifestation. In particular, its risk of cardiovascular infection calls for effective clinical intervention strategies. The multiple values of heparin in its cardiovascular sy...

Descripción completa

Detalles Bibliográficos
Autor principal:	Yu, Xianqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486575/ https://www.ncbi.nlm.nih.gov/pubmed/34627645 http://dx.doi.org/10.1016/j.ajem.2021.09.067

Ejemplares similares

Potential value of neuroimmunotherapy for COVID-19: efficacies and mechanisms of vagus nerve stimulation, electroacupuncture, and cholinergic drugs
por: Yu, Xianqiang, et al.
Publicado: (2023)

Novel Coronavirus and Its Potential Risk of Triggering Inflammatory Disease of the Abdomen during COVID-19: Endoscopic Application
por: Yu, Xianqiang
Publicado: (2021)

Horizons of Heparin Therapy in COVID-19 and Pandemic-Related Diseases
por: Kondashevskaya, M. V.
Publicado: (2022)

Potential of heparin and nafamostat combination therapy for COVID‐19
por: Asakura, Hidesaku, et al.
Publicado: (2020)

Prognostic value of heparin-binding protein for mortality in severe COVID-19 pneumonia
por: Acar, Tarık, et al.
Publicado: (2022)

Heparin mimetics as potential intervention for COVID-19 and their bio-manufacturing
por: Jiang, Lan, et al.
Publicado: (2022)

Nebulized Heparin for Post-COVID-19-Related Hypoxia
por: Hursitoglu, Mehmet, et al.
Publicado: (2021)

COVID-19 changes the lifestyle of the population and subtly reduces the incidence of metabolic disease
por: Yu, Xianqiang
Publicado: (2021)

Surviving Covid-19 with Heparin?
por: ten Cate, Hugo
Publicado: (2021)

The versatile heparin in COVID‐19
por: Thachil, Jecko
Publicado: (2020)

How to assess hypercoagulability in heparin-induced thrombocytopenia? Biomarkers of potential value to support therapeutic intensity of non-heparin anticoagulation
por: Barocas, Antoine, et al.
Publicado: (2023)

Comprehensive Landscape of Heparin Therapy for COVID-19
por: Shi, Chen, et al.
Publicado: (2021)

A Case of COVID-19 Related Coagulopathy Complications and Heparin Resistance
por: Chowdhry, Erum, et al.
Publicado: (2021)

Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection
por: Magnani, Harry N.
Publicado: (2021)

Heparin-induced thrombocytopenia and COVID-19
por: Sartori, Michelangelo, et al.
Publicado: (2021)

Heparin-Induced Thrombocytopenia in COVID-19
por: Lingamaneni, Prasanth, et al.
Publicado: (2020)

Heparin Mimetics: Their Therapeutic Potential
por: Mohamed, Shifaza, et al.
Publicado: (2017)

Heparin-Induced Thrombocytopenia in Severe COVID-19
por: Daviet, Florence, et al.
Publicado: (2020)

Heparin Induced Thrombocytopenia in Patients with COVID-19
por: Warrior, Surbhi, et al.
Publicado: (2020)

Type and dose of heparin in Covid‐19: Reply
por: Thachil, Jecko, et al.
Publicado: (2020)

Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
por: Volteas, Panagiotis, et al.
Publicado: (2022)

The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review
por: Gozzo, Lucia, et al.
Publicado: (2020)

Caution of the Etiology of Testicular Swelling in the Context of COVID-19 Pandemic—It May Not Be Testicular Torsion
por: Yu, Xianqiang
Publicado: (2021)

Impact of COVID-19 on monitoring of therapeutic unfractionated heparin
por: Adie, Sarah K., et al.
Publicado: (2020)

Heparin and related polysaccharides : structure and activities
Publicado: (1989)

Cardiovascular Complications Related to COVID-19 Disease
por: Alsatli, Raed A.
Publicado: (2020)

Editorial: Heparin and Related Polysaccharides
por: Gray, Elaine, et al.
Publicado: (2020)

Heparin-Related Major Bleeding in Covid-19-Positive Patient: Perspective from the Outbreak
por: Lucatelli, Pierleone, et al.
Publicado: (2020)

Reply to Rheumatologists’ perspective on coronavirus disease 19: is heparin the dark horse for COVID-19?
por: Ahmed, Sakir, et al.
Publicado: (2020)

Heparin-Binding Protein: A Novel Biomarker Linking Four Different Cardiovascular Diseases
por: Cai, Yufeng, et al.
Publicado: (2020)

New characteristics of testicular torsion in children during COVID-19
por: Yu, Xianqiang, et al.
Publicado: (2021)

The potential impact of Covid-19 on the capacity of routine laboratory tests to detect heparin-induced thrombocytopenia
por: Draxler, Dominik F., et al.
Publicado: (2022)

Spontaneous Heparin-Induced Thrombocytopenia and COVID-19 Infection
por: Amara, Suneetha
Publicado: (2021)

COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis
por: Perna, Alessandra F., et al.
Publicado: (2020)

Non-anticoagulant heparin derivatives for COVID-19 treatment
por: Cao, Min, et al.
Publicado: (2023)

Impact of low molecular weight heparin administration on the clinical course of the COVID-19 disease
por: YORMAZ, Burcu, et al.
Publicado: (2021)

Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia
por: Costanzo, Luca, et al.
Publicado: (2020)

Use of low-molecular-weight heparin in COVID-19 patients
por: Kow, Chia Siang, et al.
Publicado: (2020)

Heparin resistance in COVID-19 patients in the intensive care unit
por: White, D., et al.
Publicado: (2020)

The association between treatment with heparin and survival in patients with Covid-19
por: Ayerbe, Luis, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0g5hieakmcdvdaralhbl8393da